Research area · Tissue & repair research

Peptide recovery research: mostly animal and cell studies

Most tissue-repair research on BPC-157 and TB-500 comes from animal and cell studies. This page shows what has been studied, how far it has gone, and where each compound stands legally. If you searched for “peptides for recovery”, this is the page for that research area.

  • Evidence grade or review status for every compound
  • Sources listed on every page
  • US and sport status, dated
2 compoundsPreclinical
Updated Nov 2026Dated on every page
BPC-157 TB-500
Short answerResearch area · Updated 18 Nov 2026

Most tissue-repair research on BPC-157 and TB-500 comes from animal and cell studies. Human data on BPC-157 come from a few small studies, most without a control group; its only randomized, placebo-controlled data are in conference abstracts, and no peer-reviewed randomized trial has been published. One randomized trial of the TB-500 fragment of thymosin β4 is registered and recruiting, with no results yet. Neither is an FDA-approved medicine.

The research so far

What has research on BPC-157 and TB-500 studied?

In a 2003 study, researchers cut the Achilles tendon in rats and measured how it healed after BPC-157. A 2006 study looked at Achilles detachment. These are animal results, not evidence of an effect in people. [1] [2]

Human data on BPC-157 come from a few small studies, most without a control group. The only randomized, placebo-controlled data are in conference abstracts from 2002 to 2005; no peer-reviewed randomized trial has been published. [3] [16]

Several human studies of BPC-157 are registered on ClinicalTrials.gov, including a phase 2 trial in hamstring strain (recruiting) and a phase 1 trial after rotator cuff repair (not yet recruiting). As of November 2026, none has posted results. [4] [5] [13]

Human trials of the full 43-amino-acid thymosin β4 protein include eye drops and a skin gel. None of them tested TB-500. One randomized trial of the fragment itself is registered and recruiting, with no results yet. [6] [10] [11] [12]

Evidence grades

How far has the research on BPC-157 and TB-500 gone?

Pick a compound to see the highest rung reached, from cell study to approval.

Cell studies
—
Animal studies
—
Human pilot / case series
—
Controlled human trials
—
Regulatory approval
—
Highest rung reached
—

How we grade evidence

What doesn’t the research on BPC-157 and TB-500 show?

Saying what we don't know is part of the evidence.

Any effect of BPC-157 or TB-500 in people from a peer-reviewed controlled trial.

Anything about BPC-157 and TB-500 used together in people: no controlled human study has tested the pair.

Are BPC-157 and TB-500 FDA-approved medicines? US and sport status

As of November 2026. See the full tracker and the changelog.

CompoundFDA approval503A compounding (2026)WADA (2026 List)
BPC-157Not approvedFDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yetProhibited (S0, named)
TB-500Not approvedFDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yetProhibited (S2, named)

Worth knowing

Research use only

None of the compounds on this page is an FDA-approved medicine. Nothing on this page is medical advice or describes use in people.

What research use only means

No doses, ever

We publish no doses, protocols, or cycles for people, on any page.

Why we publish no doses

How we grade evidence

Grades follow study design: cell and animal studies (preclinical), small human studies, then controlled human trials, with approval tracked separately. A grade is not a promise of any effect.

Evidence grades

Questions people ask

Is there human evidence for BPC-157?

Human data come from a few small studies, most without a control group. The only randomized, placebo-controlled data are in conference abstracts; no peer-reviewed randomized trial has been published. Several human studies are registered; as of November 2026, none has posted results.

Is TB-500 the same as thymosin β4?

Not as FDA and HHS describe it: their documents define TB-500 as a seven-amino-acid fragment of the 43-amino-acid protein. Products sold under the name vary; the mass on the lab report tells you which is in the vial.

What did the October 2026 HHS policy change?

HHS said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, and licensed physicians compounding BPC-157, TB-500, and four other peptides under ten conditions, including a patient-specific prescription, while the list of permitted ingredients goes through rulemaking. The Federal Register notice calls the policy a draft; it is not binding and not an approval. It does not cover peptides sold for research use only: HHS says it aims to discourage the widespread use of certain research-use-only peptides supplied by foreign manufacturers.

Sources

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976–983. PMID 14554208. doi.org/10.1016/S0736-0266(03)00110-4
  2. Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982–989. PMID 16583442. pubmed.ncbi.nlm.nih.gov/16583442/
  3. McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611–619. PMID 40789979. pubmed.ncbi.nlm.nih.gov/40789979/
  4. ClinicalTrials.gov. NCT07437547: BPC 157 for acute hamstring muscle strain repair (phase 2). clinicaltrials.gov/study/NCT07437547
  5. ClinicalTrials.gov. NCT07803250: Impact of BPC-157 on recovery following rotator cuff repair surgery (phase 1). clinicaltrials.gov/study/NCT07803250
  6. Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. 2015;9:877–884. PMID 26056426. pubmed.ncbi.nlm.nih.gov/26056426/
  7. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, 28 Oct 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
  8. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting page, 23–24 July 2026: agenda, voting questions and FDA briefing (no minutes posted as of 17 November 2026). www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  9. World Anti-Doping Agency. Prohibited List 2026 (in force 1 January 2026) and 2027 (in force 1 January 2027). www.wada-ama.org/en/prohibited-list
  10. Sosne G, et al. 0.1% RGN-259 (thymosin ß4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked phase III clinical trial. Int J Mol Sci. 2022;24(1):554. PMID 36613994. pubmed.ncbi.nlm.nih.gov/36613994/
  11. ClinicalTrials.gov. NCT00832091: Study of thymosin beta 4 in patients with venous stasis ulcers (phase 2). clinicaltrials.gov/study/NCT00832091
  12. ClinicalTrials.gov. NCT07487363: TB-500 (thymosin beta 4 17-23 fragment) for cardiovascular biomarkers in stable ASCVD (phase 1/2, recruiting). clinicaltrials.gov/study/NCT07487363
  13. ClinicalTrials.gov. Registered human studies of BPC-157 (search results), checked 17 November 2026. clinicaltrials.gov/search?term=BPC-157
  14. U.S. Department of Health and Human Services. Enforcement discretion policy, Appendix B: peptide identities and justifications, October 2026 (records the July 2026 committee outcome for each of the six peptides). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  15. Federal Register 91 FR 68526, 30 October 2026. Notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (the notice calls the policy a draft). www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  16. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances (pp. 27, 40–43). www.fda.gov/media/193343/download
  17. Delcourt V, et al. TB500/TB1000 and SGF1000: a scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023;15(4):458–464. PMID 36482504. pubmed.ncbi.nlm.nih.gov/36482504/

Start with the evidence

Every page sourced and dated, including what the research does not show.

Open the research library
Written by 6AM Research. Drafted with AI from published studies, trial registries, and regulator documents, plus press reports where marked. Every page lists its sources and is dated. Editorial policy · Corrections
Education only. Nothing here is medical advice or describes use in people. Research use only